@Tinojaramillo @dgomezco @luomar Poca evidencia soporta esa hipótesis. La confidencialidad impide saber a qué parte se está beneficiando. Y sí se cede mucho en el poder de negociación a la farmacéutica. Ejemplo: https://t.co/dehy2V9A0o
RT @a_ferrario: Implementation of Managed Entry Agreements in Central and Eastern Europe published open access in Pharmacoeconomics: https:…
RT @a_ferrario: Implementation of Managed Entry Agreements in Central and Eastern Europe published open access in Pharmacoeconomics: https:…
RT @a_ferrario: Implementation of Managed Entry Agreements in Central and Eastern Europe published open access in Pharmacoeconomics: https:…
RT @a_ferrario: Implementation of Managed Entry Agreements in Central and Eastern Europe published open access in Pharmacoeconomics: https:…
Implementation of Managed Entry Agreements in Central and Eastern Europe published open access in Pharmacoeconomics: https://t.co/av6VDLw6h8
RT @PECjournal: Should confidential price agreements be tolerated as part of risk sharing schemes in Europe https://t.co/CTsgqOXdQT
RT @PECjournal: Should confidential price agreements be tolerated as part of risk sharing schemes in Europe https://t.co/CTsgqOXdQT
Should confidential price agreements be tolerated as part of risk sharing schemes in Europe https://t.co/CTsgqOXdQT
#HealthEconJA The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implicati… https://t.co/PCeCrihUp7